Recordati Industria Chimica e Farmaceutica S.p.A. (BIT: REC)

Market Cap	10.20B
Revenue (ttm)	2.27B
Net Income (ttm)	423.12M
Shares Out	204.48M
EPS (ttm)	2.02
PE Ratio	24.67
Forward PE	20.22
Dividend	1.20 (2.40%)
Ex-Dividend Date	Nov 18, 2024

Volume	88,176
Open	50.15
Previous Close	50.00
Day's Range	49.92 - 50.55
52-Week Range	43.88 - 54.80
Beta	0.40
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 8, 2024

About REC

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing’s syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis. T...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1926
• Employees: 4,455
• Stock Exchange: Borsa Italiana
• Ticker Symbol: REC

Financial Performance

In 2023, REC's revenue was 2.08 billion, an increase of 12.36% compared to the previous year's 1.85 billion. Earnings were 389.21 million, an increase of 24.61%.